Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:284706.
doi: 10.1155/2015/284706. Epub 2015 Oct 11.

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development

Holly L Geyer  1 , Amylou C Dueck  2 , Robyn M Scherber  3 , Ruben A Mesa  3
Affiliations
Review

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development

Holly L Geyer et al. Mediators Inflamm. 2015.

Abstract

Myeloproliferative neoplasms (essential thrombocythemia, ET; polycythemia vera, PV; myelofibrosis, MF) are monoclonal malignancies associated with genomic instability, dysregulated signaling pathways, and subsequent overproduction of inflammatory markers. Acknowledged for their debilitating symptom profiles, recent investigations have aimed to determine the identity of these markers, the upstream sources stimulating their development, their prevalence within the MPN population, and the role they play in symptom development. Creation of dedicated Patient Reported Outcome (PRO) tools, in combination with expanded access to cytokine analysis technology, has resulted in a surge of investigations evaluating the potential associations between symptoms and inflammation. Emerging data demonstrates clear relationships between individual MPN symptoms (fatigue, abdominal complaints, microvascular symptoms, and constitutional symptoms) and cytokines, particularly IL-1, IL-6, IL-8, and TNF-α. Information is also compiling on the role symptoms paradoxically play in the development of cytokines, as in the case of fatigue-driven sedentary lifestyles. In this paper, we explore the symptoms inherent to the MPN disorders and the potential role inflammation plays in their development.

PubMed Disclaimer

References

    1. Cervantes F., Dupriez B., Pereira A., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment. Blood. 2009;113(13):2895–2901. doi: 10.1182/blood-2008-07-170449. - DOI - PubMed
    1. Gangat N., Caramazza D., Vaidya R., et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology. 2011;29(4):392–397. doi: 10.1200/jco.2010.32.2446. - DOI - PubMed
    1. Scherber R., Dueck A. C., Johansson P., et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–408. doi: 10.1182/blood-2011-01-328955. - DOI - PubMed
    1. Mesa R., Miller C. B., Thyne M., et al. Impact of myeloproliferative neoplasms (MPNs) on patients' overall health and productivity: results from the MPN LANDMARK SURVEY in the United States. Blood. 2014;124(21):p. 3183.
    1. Geyer H., Dueck A. C., Emanuel R. M., et al. Insomnia, quality of life and MPN symptom burden: an analysis by the MPN quality of life international study group (MPN-QOL ISG) Blood. 2013;122(21):p. 4087.